GameSquare expands strategic focus by bringing top gaming related events to the U.S. and adds new $2 million credit facility from Jones Family to support rapidly growing experiences business
GameSquare divests remaining 25.5% stake in FaZe Media to Gigamoon Media and FaZe's founders as part of ongoing strategy to streamline operations, further improve balance sheet and pursue profitability
GameSquare continues to own 100% of profitable FaZe Esports, one of the world's top-performing and highest winning esports organizations
GameSquare to announce Q4 2024 earnings and provide profit focused financial expectations for 2025 on April 16, 2025
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
Read More
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023
The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million
Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025
FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer
REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast
Read MoreCompany Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024
Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26
Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially
Stockholders' Equity Was $7.1 Million at Year End
Pending Acquisitions Remain on Track; TRNR Expects More than $50M in 2025 Pro Forma Revenue
Read MoreAnnual Revenue Increased 88.66%, While Annual Net Income Increased 663.27%
Ended 2024 With Cash and Investments in US Treasury Notes Totaling $16,091,024
Achieved Nine Consecutive Quarters of GAAP Profitability
Read MoreAppalachian Mountain Energy, the joint venture, will drill new wells and rework existing wells currently owned and operated by Mountain V Oil & Gas across all 300,000 surface and mineral acres across the Appalachian Basin and Permian Basin that are currently held by production by Mountain V Oil & Gas.
Read More
"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation."
DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer.
Read More
ALT5 Achieves Record-Breaking Q4 with $5.4 Million in Revenue
Customer Base Surpasses 1,000 Accounts, a Historic Milestone
Strong Annual Gross Margin of 50.2% and Impressive 18.2% Adjusted EBITDA¹ for Fintech
Significant Working Capital Improvement of $4.5 Million Over Q3
Ron Pitters Appointed as New Chief Operating Officer
Rekortan will support with track quality and maintenance, warm-up areas, equipment provision, and other sports surfaces for Slams in Kingston, Miami, Philadelphia, and Los Angeles
Read MoreCompletion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets
Read More
Despite differences in characteristics and treatment, the pFCG test distinguished risk of the primary ischemic endpoint to a similar extent in the 2 groups.
No significant association was observed between pFCG and risk of bleeding.
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA
In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need
Read MoreSuccessful Integration: Nixxy integrates newly acquired telecom AI software into its Auralink AI telcom subsidiary
Immediate Revenue Impact: Auralink AI is expected to generate initial revenue of $250,000 for March, and $2 million in April 2025
Strategic Vision: Management strategically positions Auralink AI for expansion, delivering innovative, AI-powered billing and LCR solutions to the Communications Platform as a Service (CpaaS) industry
